+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiac Resynchronization Therapy (CRT Devices) Devices (Cardiovascular Devices) - Global Market Analysis and Forecast Model

  • Report

  • December 2018
  • Region: Global
  • GlobalData
  • ID: 4720197
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Cardiac Resynchronization Therapy (CRT Devices) Devices (Cardiovascular Devices) - Global Market Analysis and Forecast Model


Cardiac Resynchronization Therapy (CRT Devices) Devices (Cardiovascular Devices) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

The global prevalence of Heart Failure (HF) is one of the major drivers for Cardiac Resynchronisation Therapy (CRT). It is estimated that the prevalent cases of HF are over 23 million worldwide, 5.8 million in the United States and around 550,000 cases are diagnosed each year. Cardiac Resynchronisation Therapy - defibrillator uses an Implantable Cardioverter Defibrillator (ICD) to improve the coordination of the heart rhythm. This device utilizes three leads, one to the right atrium and one in each of the ventricles. Cardiac Resynchronisation Therapy - pacemaker uses a pacemaker device to improve the coordination of the heart rhythm. This device utilizes three leads, one to the right atrium and one in each of the ventricles.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions

Currently marketed cardiac resynchronization therapy and evolving competitive landscape -
  • Insightful review of the key industry trends.

  • Annualized total cardiac resynchronization therapy market revenue by segment and market outlooks from 2015-2028.

  • Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -
  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition analysts provide unique country specific insights on the market.

  • SWOT analysis for Cardiac Resynchronization Therapy (CRT Devices) market.

  • Competitive dynamics insights and trends provided for Cardiac Resynchronization Therapy (CRT Devices) market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • Country specific overview of the healthcare system.

  • Country specific reimbursement policies.

  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Medtronic plc, Abbott Laboratories, Boston Scientific Corp, Biotronik AG, MicroPort Scientific Corp, MEDICO S.p.A., Lepu Medical Technology Co., Ltd., Shree Pacetronix Ltd.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.


This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
  • CMO executives who must have deep understanding of the cardiac resynchronization therapy marketplace to make strategic planning and investment decisions.

  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving cardiac resynchronization therapy market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the cardiac resynchronization therapy market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Track device sales in the global and country-specific cardiac resynchronization therapy market from 2015-2028.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Medtronic plc

  • Abbott Laboratories

  • Boston Scientific Corp

  • Biotronik AG

  • MicroPort Scientific Corp

  • MEDICO S.p.A.

  • Lepu Medical Technology Co. Ltd.

  • Shree Pacetronix Ltd